LEO Reports 16-week Results of Tralokinumab in P-III ECZTRA 6 Trial for the Treatment of Moderate-to-Severe Atopic Dermatitis Published: 22 Oct, 2021 | Tags: LEO, Tralokinumab, P-III, ECZTRA 6 Trial, […]readmore
Tags : Specialised Therapeutics
Shots: Incyte will lead the development, manufacture, and supply of both products. ST will be responsible for the regulatory, distribution, and local marketing related activities in Australia, New Zealand & […]readmore
Shots: Onconova to get clinical, regulatory and sales-based milestones up to $30.4M and royalties on sales. Specialised to receive exclusive rights to commercialize rigosertib in Australia and New Zealand The […]readmore